Uncategorized

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

By Erin Brodwin

How Pinterest beat back vaccine misinformation — and what Facebook could learn from its approach

Pharma By Adam Feuerstein

Merck chronic cough drug shows mixed results in late-stage clinical trials, raising questions about its future

By Rebecca Robbins, Casey Ross, and Erin Brodwin

STAT Health Tech: Elon Musk’s secretive brain implants startup & Verily’s move into health insurance

By Nicholas Florko

House Democrats are using the budget process to slam the Trump administration’s Covid-19 response

By Matthew Herper

Eli Lilly gets an edge against Pfizer in adjuvant breast cancer

Pharmalot By Ed Silverman

California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents

By Lev Facher

6 takeaways from the Senate’s surreal virtual hearing on the U.S. coronavirus response

By Shraddha Chakradhar

Last chance! Sign up for our STAT Plus event – “Gene therapy has arrived. What’s next?”

Biotech By Adam Feuerstein

Karyopharm to seek expanded use of multiple myeloma drug following positive clinical trial

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Drug industry infighting, the human side of genetic medicine, and a big year for the microbiome

Pharma By Jonathan Saltzman — Boston Globe

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

By STAT

[email protected] 2020

Biotech By Matthew Herper

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

Politics By Lev Facher

Insurance, pharma figures spar over drug price legislation’s innovation impact

Biotech By Jonathan Saltzman — Boston Globe

New MS drug from Biogen and Alkermes wins approval

Pharmalot By Ed Silverman

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

By Shraddha Chakradhar

STAT Plus: Our fourth quarter biotech scorecard

Biotech By Jonathan Saltzman — Boston Globe

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

Business By Matthew Herper

Illumina confronts the innovator’s dilemma

Health By Matt Stout — Boston Globe

Mass. declares public health emergency, orders 4-month ban on all vaping products

Biotech By Damian Garde

A biotech startup hopes to disarm cancer by targeting a genetic bandolier

Biotech By Isabella Tran — Boston Globe

Biotech industry aims to spark girls’ interests in science long before high school

Biotech By Damian Garde

Myovant’s uterine fibroid drug meets goals in trial, setting up competition with AbbVie

Biotech By Matthew Herper

Most Read

Health websites are notoriously misleading. So we rated their reliability

An updated guide to the changing science of flu shots

STAT China: Two more Hong Kong IPO filings, and Beijing’s latest drug price cuts

Scientists can track the spread of opioids in sewers. But do cities want to know what lies below?

Covid-19 test accuracy supplement: The math of Bayes’ Theorem

In New Hampshire, Trump stands by universal health care in face of Cruz attacks

AbbVie may face fewer wrinkles after judge suggests a 10-year ban on a Botox rival

Night sweats, bloody cough — and a diagnosis that turned a doctor into an activist

All Coverage

Up and down the ladder: The latest comings and goings

How Pinterest beat back vaccine misinformation — and what Facebook could learn from its approach

Merck chronic cough drug shows mixed results in late-stage clinical trials, raising questions about its future

STAT Health Tech: Elon Musk’s secretive brain implants startup & Verily’s move into health insurance

House Democrats are using the budget process to slam the Trump administration’s Covid-19 response

Eli Lilly gets an edge against Pfizer in adjuvant breast cancer

California supports an attorney’s unusual whistleblower lawsuit against ‘fraudulent’ patents

6 takeaways from the Senate’s surreal virtual hearing on the U.S. coronavirus response

Last chance! Sign up for our STAT Plus event – “Gene therapy has arrived. What’s next?”

Karyopharm to seek expanded use of multiple myeloma drug following positive clinical trial

Listen: Drug industry infighting, the human side of genetic medicine, and a big year for the microbiome

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

[email protected] 2020

Cleveland Clinic’s Nissen denies any communication with FDA about Amarin’s Vascepa

Insurance, pharma figures spar over drug price legislation’s innovation impact

New MS drug from Biogen and Alkermes wins approval

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

STAT Plus: Our fourth quarter biotech scorecard

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

Illumina confronts the innovator’s dilemma

Mass. declares public health emergency, orders 4-month ban on all vaping products

A biotech startup hopes to disarm cancer by targeting a genetic bandolier

Biotech industry aims to spark girls’ interests in science long before high school

Myovant’s uterine fibroid drug meets goals in trial, setting up competition with AbbVie

Alector, with big ideas about treating dementia, presents a little bit of data